Torrent Pharma Announces Strong Q1 FY25 Results With 21 Percent Net Profit Increase
The company informed that its revenue reached Rs. 2,859 crores, reflecting a 10 per cent increase compared to the same period last year
Torrent Pharmaceuticals in a press statement on Wednesday revealed its financial results for Q1 FY25, demonstrating robust growth across multiple business segments.
The company informed that its revenue reached Rs. 2,859 crores, reflecting a 10 per cent increase compared to the same period last year. Gross margin stood at 75.7 per cent, while operational EBITDA margin was 31.6 per cent, marking a growth of 14 per cent. Net profit after tax surged by 21 per cent to Rs. 457 crores, the company further stated.
The company faced one-off expenses of Rs. 20 crores in its international business, impacting overall profitability. However, when adjusted for these expenses, the underlying operational EBITDA was Rs. 924 crores, with an adjusted EBITDA margin of 32.3 per cent.
Performance Summary:
| Results | Q1 FY25 | Q1 FY24 | YoY% |
|---|---|---|---|
| Rs cr | % | Rs cr | % |
| Revenues | 2,859 | - | 2,591 |
| Gross profit | 2,165 | 76 per cent | 1,941 |
| Op EBITDA | 904 | 32 per cent | 791 |
| PAT | 457 | 16 per cent | 378 |
| R&D spend | 135 | 5 per cent | 129 |
The statement further informed that Torrent's India revenues increased by 15 per cent to Rs 1,635 crores, driven by strong performance in focus therapies. The company's chronic business grew by 14 per cent, outperforming the Indian Pharmaceutical Market (IPM) growth of 8 per cent, supported by a revival in cardiac divisions and new anti-diabetes (OAD) launches. Torrent also entered into a non-exclusive licensing agreement with Takeda and commercialised Vonoprazan during the quarter. Brazil's revenues grew by 3 per cent to Rs 196 crores, with constant currency revenues up by 8 per cent. Torrent's growth in Brazil was 12 per cent compared to the market growth of 11 per cent, despite primary sales being affected by severe floods in Rio Grande do Sul. During Q1, Torrent received ANVISA approval for three new products, including Lisdexanfetamine, which is expected to drive significant growth in Q2 24-25. Germany's revenues rose by 10 per cent to Rs 284 crores, with constant currency revenues up by 9 per cent.
The company continues to see growth momentum with incremental tender wins over the last five quarters, expected to generate additional sales from Q2 onwards. US business revenues declined by 12 per cent to Rs 259 crores, with constant currency revenues down by 13 per cent compared to the same period last year.
_20240724175817_original_image_20.webp)
